How To Decarbonize Pharma R&D

As the planet heats up and sea levels rise, the need to reduce carbon emissions is becoming ever more urgent. The life sciences industry is just one of many that are looking to cut the carbon it produces.  

Climate Change
Regulators across the world should collaborate to design pathways that help decarbonize drug development • Source: Shutterstock

Drug manufacturing and supply chains may be more obvious targets for slashing emissions, but so too is R&D. Researchers should look to greater collaboration, adaptive trials and slashing “low value research,” among other things, to reach net zero targets, according to speakers at the 3 September Westminster Health Forum policy conference entitled “Next steps for decarbonization in the UK life sciences sector.”

Key Take Aways

  • R&D should also be a target for decarbonizing the life sciences sector.

Global warming is having a negative impact on health, for example, respiratory patients are suffering more exacerbations through deteriorating air...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from ESG

More from In Vivo

Deals In Depth: June 2025

 
• By 

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By 

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By 

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.